Role of Asymmetric Dimethylarginine in Vascular Injury in Transgenic Mice Overexpressing Dimethylarginie Dimethylaminohydrolase 2
- 20 July 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 101 (2), e2-10
- https://doi.org/10.1161/circresaha.107.156901
Abstract
Dimethylarginie dimethylaminohydrolase (DDAH) degrades asymmetric dimethylarginine (ADMA), an endogenous nitric oxide (NO) synthase inhibitor, and comprises 2 isoforms, DDAH1 and DDAH2. To investigate the in vivo role of DDAH2, we generated trangenic mice overexpressing DDAH2. The transgenic mice manifested reductions in plasma ADMA and elevations in cardiac NO levels but no changes in systemic blood pressure (SBP), compared with the wild-type mice. When infused into wild-type mice for 4 weeks, ADMA elevated SBP and caused marked medial thickening and perivascular fibrosis in coronary microvessels, which were accompanied by ACE protein upregulation and cardiac oxidative stress. The treatment with amlodipine reduced SBP but failed to ameliorate the ADMA-induced histological changes. In contrast, these changes were abolished in transgenic mice, with a reduction in plasma ADMA. In coronary artery endothelial cells, ADMA activated p38 MAP kinase and the ADMA-induced ACE upregulation was suppressed by p38 MAP kinase inhibition by SB203580. In wild-type mice, long-term treatment with angiotensin II increased plasma ADMA and cardiac oxidative stress and caused similar vascular injury. In transgenic mice, these changes were attenuated. The present study suggests that DDAH2/ADMA regulates cardiac NO levels but has modest effect on SBP in normal conditions. Under the circumstances where plasma ADMA are elevated, including angiotensin II–activated conditions, ADMA serves to contribute to the development of vascular injury and increased cardiac oxidative stress, and the overexpression of DDAH2 attenuates these abnormalities. Collectively, the DDAH2/ADMA pathway can be a novel therapeutic target for vasculopathy in the ADMA or angiotensin II–induced pathophysiological conditions.Keywords
This publication has 30 references indexed in Scilit:
- Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing heartsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Dimethylarginine Dimethylaminohydrolase Overexpression Suppresses Graft Coronary Artery DiseaseCirculation, 2005
- Angiotensin-converting enzyme inhibitors prevent LDL-induced endothelial dysfunction by reduction of asymmetric dimethylarginine levelInternational Journal of Cardiology, 2005
- Asymmetric Dimethylarginine Produces Vascular Lesions in Endothelial Nitric Oxide Synthase–Deficient MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertensionAmerican Heart Journal, 2004
- Mice Lacking Endothelial ACEHypertension, 2003
- Superoxide Generation in Directional Coronary Atherectomy Specimens of Patients With Angina PectorisArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Peroxisome Proliferator-activated Receptor γ Ligands Inhibit Mitogenic Induction of p21Cip1 by Modulating the Protein Kinase Cδ Pathway in Vascular Smooth Muscle CellsPublished by Elsevier BV ,2001
- Downregulation of Angiotensin-Converting Enzyme by Tumor Necrosis Factor-α and Interleukin-1β in Cultured Human Endothelial CellsJournal of Vascular Research, 2001
- Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failureThe Lancet, 1992